ALLMedicine™ Ulcerative Colitis Center

Mar 28th, 2023 - Patients with inflammatory bowel disease (IBD) are at a higher risk of developing cardiovascular diseases than healthy individuals, owing to persistent chronic inflammation and treatment effects. This study aimed to assess left ventricular functio...

Mar 28th, 2023 - Ulcerative colitis is an inflammatory bowel disease that is mainly related to gut microbiota dysbiosis. Lactobacillus plantarum ZJ316 (ZJ316) has been proved to regulate the gut microbiota in vitro. However, more evidence is needed for the intesti...

Mar 27th, 2023 - Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) remains the preferred surgical option for medically refractory ulcerative colitis. Management of individuals with an IPAA prior to and during pregnancy presents challenges that c...

Mar 27th, 2023 - The appropriate location for biopsy collection in ulcerative colitis is unknown. We aimed to determine the location for biopsy collection in the presence of ulcers which yields the highest histopathological score. This prospective cross-sectional ...

Mar 26th, 2023 - In peripheral blood, DNA methylation (DNAm) patterns in inflammatory bowel disease patients reflect inflammatory status rather than disease status. Here, we examined DNAm in diseased rectal mucosa from ulcerative colitis (UC) patients, focusing on...

Feb 24th, 2023 - Biomarkers are used frequently for noninvasive monitoring and treatment decision making in the management of patients with ulcerative colitis (UC). This American Gastroenterological Association (AGA) guideline is intended to support practitioners ...

Sep 9th, 2021 - The properties of the saliva of patients with inflammatory bowel disease (IBD) are poorly recognized. Likewise, the diagnostic potential of saliva for differentiating various forms of IBD is largely unexplored. Therefore, we compared the concentra...

Oct 22nd, 2020 - Endoscopy is an essential component in the management of inflammatory bowel disease [IBD]. There is a risk of SARS-CoV-2 transmission during endoscopic procedures. The International Organization for the study of IBD [IOIBD] has developed 11 positi...

Mar 29th, 2020 - Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcerative Colitis: Clinical Decision Support Tool.|2020| ,|

Mar 15th, 2020 - Spotlight: Management of Moderate-to-Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|

Mar 24th, 2023 - This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC).

Mar 17th, 2023 - This is an observational prospective study with two years of follow-up, designed to evaluate the effectiveness of tofacitinib in patients with moderate to severe ulcerative colitis in French clinical practice

Mar 16th, 2023 - The primary objective is to evaluate the efficacy and dose response of 3 different dose regimens of TEV-48574 in adult participants with IBD (moderate to severe Ulcerative Colitis (UC) or Crohn's Disease (CD)) as assessed by induction of clinical ...

Mar 15th, 2023 - UC is a chronic disease of the large intestine, in which the lining of the colon becomes inflamed and develops ulcers. Guselkumab is a fully human immunoglobulin G1 lambda monoclonal antibody (mAb) that binds to human interleukin (IL)-23 with high...

Mar 15th, 2023 - This is an open-label (both [participants and investigator] know what treatment participants will receive) and multicenter study. The study is divided into 2 parts: Part 1: pharmacokinetics portion (Week 0 to Week 14); Part 2: study extension (Wee...

Mar 13th, 2023 - In new evidence-based guidelines, the American Gastroenterological Association recommends noninvasive biomarkers as a first-line strategy for monitoring many patients with ulcerative colitis (UC). These guidelines were published in Gastroenterolog.

Mar 7th, 2023 - Induction therapy with a novel interleukin 6 (IL-6) inhibitor for active ulcerative colitis yielded significantly higher rates of clinical response, remission, and mucosal healing than placebo, findings from a phase II study conducted in Asia show...

Mar 3rd, 2023 - COPENHAGEN – Vedolizumab (ENTYVIO) a monoclonal antibody drug, shows a higher overall 1- and 2-year persistence of use – the overall time that a patient stays on a medication – compared with two anti–tumor necrosis factor inhibitors (anti-TNFi) in.

Mar 3rd, 2023 - Evolving endpoints and treat-to-target strategies in inflammatory bowel disease (IBD) incorporate a need for more frequent assessments of the disease, including objective measures of inflammation. 1,2 Intestinal ultrasound (IUS) is a noninvasive, w.

Feb 23rd, 2023 - The American Gastroenterological Association (AGA) has released a new clinical practice guideline defining the role of biomarkers in monitoring and managing ulcerative colitis (UC). There is growing data on how to incorporate biomarkers in the car.